Want to see JP:7459 full AI Analyst Report?
Top Page
Medipal Holdings
(7459)
Select Model
Select Model
Rating:72Outperform
Price Target:
¥3,559.00
▲(23.02% Upside)
Action:Upgraded
Date:08/17/26
The score is driven primarily by strong financial stability (very low leverage and steady revenue growth), tempered by thin margins and uneven cash flow. Technicals are neutral-to-mixed with modest momentum, and valuation is reasonable with a moderate P/E and a supportive dividend yield.
Positive Factors
Steady Revenue Growth
Multi-year revenue growth indicates resilient demand for Medipal’s scale-driven healthcare distribution model. A growing top line supports recurring replenishment volumes, strengthens network utilization, and provides a durable base for maintaining customer coverage and logistics capabilities.
Negative Factors
Structurally Thin Margins
Very thin net margins leave limited room to absorb cost increases, pricing pressure, or execution setbacks before profitability is affected. The structure also makes earnings highly dependent on distribution scale and efficiency rather than substantial pricing power or margin expansion.
Read all positive and negative factors
Positive Factors
Negative Factors
Steady Revenue Growth
Multi-year revenue growth indicates resilient demand for Medipal’s scale-driven healthcare distribution model. A growing top line supports recurring replenishment volumes, strengthens network utilization, and provides a durable base for maintaining customer coverage and logistics capabilities.
Read all positive factors
Medipal Holdings (7459) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥581.61B
Dividend Yield2.43%
Average Volume (3M)444.37K
Price to Earnings (P/E)14.1
Beta (1Y)0.38
Revenue Growth4.17%
EPS Growth15.59%
CountryJP
Employees13,024
SectorHealthcare
Sector Strength45
IndustryMedical - Distribution
Share Statistics
EPS (TTM)227.17
Shares Outstanding215,975,040
10 Day Avg. Volume322,190
30 Day Avg. Volume444,373
Financial Highlights & Ratios
PEG Ratio2.04
Price to Book (P/B)0.93
Price to Sales (P/S)0.16
P/FCF Ratio15.14
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥2,900.00Price Target Upside0.24% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)233.84
Revenue Forecast (FY)¥3.94T
Medipal Holdings Business Overview & Revenue Model
Company Description
Medipal Holdings Corporation, a Tokyo, Japan-based company founded in 1898, primarily specializes in the wholesale distribution of prescription pharmaceuticals throughout Japan. The firm procures a broad spectrum of healthcare products, including ...
How the Company Makes Money
Medipal Holdings makes money primarily through wholesale distribution. Its main revenue model is selling products it procures from manufacturers (e.g., pharmaceutical makers and other healthcare suppliers) to healthcare providers and retail channe...
Medipal Holdings Financial Statement Overview
Summary
Income Statement
67
Positive
Balance Sheet
86
Very Positive
Cash Flow
63
Positive
| Breakdown | TTM | Mar 2026 | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.86T | 3.82T | 3.67T | 3.56T | 3.36T | 3.29T |
| Gross Profit | 248.30B | 247.41B | 242.25B | 233.01B | 212.12B | 205.11B |
| EBITDA | 104.89B | 110.05B | 95.16B | 92.73B | 84.74B | 71.64B |
| Net Income | 46.59B | 42.53B | 40.28B | 41.48B | 38.81B | 29.42B |
Balance Sheet | ||||||
| Total Assets | 1.94T | 1.92T | 1.82T | 1.80T | 1.70T | 1.71T |
| Cash, Cash Equivalents and Short-Term Investments | 289.92B | 289.07B | 261.41B | 230.47B | 195.03B | 261.92B |
| Total Debt | 43.23B | 0.00 | 4.17B | 1.46B | 7.38B | 38.81B |
| Total Liabilities | 1.15T | 1.13T | 1.07T | 1.06T | 1.02T | 1.06T |
| Stockholders Equity | 649.73B | 652.17B | 619.57B | 600.35B | 561.36B | 530.30B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 39.93B | 51.70B | 46.28B | 5.66B | 45.26B |
| Operating Cash Flow | 0.00 | 46.55B | 60.56B | 61.84B | 16.15B | 61.22B |
| Investing Cash Flow | 0.00 | 9.30B | -3.36B | -7.82B | -39.47B | -24.34B |
| Financing Cash Flow | 0.00 | -29.40B | -25.95B | -25.25B | -43.56B | -16.47B |
Medipal Holdings Technical Analysis
Positive
2893.00
Price Trends
2931.09
Positive
2807.76
Positive
2805.91
Positive
Market Momentum
72.11
Negative
72.20
Negative
87.14
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7459, the sentiment is Positive. The current price of 2893 is below the 20-day moving average (MA) of 3039.36, below the 50-day MA of 2931.09, and above the 200-day MA of 2805.91, indicating a bullish trend. The MACD of 72.11 indicates Negative momentum. The RSI at 72.20 is Negative, neither overbought nor oversold. The STOCH value of 87.14 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:7459.
Medipal Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | ¥372.16B | 10.63 | 9.19% | 3.81% | 4.65% | 23.21% | |
72 Outperform | ¥581.61B | 14.11 | 7.26% | 2.43% | 4.17% | 15.59% | |
69 Neutral | ¥427.47B | 13.59 | 11.15% | 3.61% | 4.32% | 0.18% | |
63 Neutral | ¥459.23B | 11.14 | 7.93% | 2.87% | 4.61% | 43.22% | |
62 Neutral | ¥488.12B | 15.52 | 9.94% | 1.39% | 8.97% | -29.54% | |
56 Neutral | ¥413.54B | 21.70 | ― | 0.34% | 12.54% | 15.87% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
JP:7459
Medipal Holdings
3,206.00
658.30
25.84%
JP:2784
Alfresa Holdings
2,406.50
253.14
11.76%
JP:9989
Sundrug Co
3,656.00
-430.36
-10.53%
JP:7649
Sugi Holdings Co
1,256.00
-453.69
-26.54%
JP:9987
Suzuken Co
2,886.50
-47.91
-1.63%
JP:3549
KUSURI NO AOKI HOLDINGS CO.,LTD.
4,325.00
371.08
9.39%
Medipal Holdings Corporate Events
Medipal Launches ¥10 Billion Share Buyback and Cancellation to Lift Capital Efficiency
Oct 23, 2026
Medipal Holdings has approved a new share buyback and subsequent cancellation as part of its ongoing effort to boost capital efficiency and enhance shareholder returns. The program will be funded in part by proceeds from recent sales of investment...
Medipal Lifts Full-Year Profit Forecast on Gains from Strategic Share Sales
Oct 23, 2026
Medipal Holdings Corporation, a major Japanese pharmaceutical and healthcare products wholesaler listed on the Prime Market of the Tokyo Stock Exchange, plays a central role in the country’s medical supply chain through the distribution of m...
Medipal Books ¥15.5 Billion Gain as It Cuts Strategic Shareholdings
Oct 23, 2026
Medipal Holdings has booked an extraordinary income from the sale of a portion of its investment securities between May and October 2026, as part of a broader effort to reduce strategic shareholdings. The move aligns with Japan’s Corporate G...
Medipal Sets Record Date for Potential Extraordinary Shareholders Meeting
Oct 13, 2026
Medipal Holdings has moved to set October 31, 2026, as the record date for determining which shareholders are eligible to vote at a potential extraordinary general meeting. The decision follows a formal demand to convene such a meeting from a majo...
Medipal Holdings Reshapes Top Management to Drive Sustainable Growth
Sep 8, 2026
Medipal Holdings has announced a management reshuffle effective October 1, 2026, aimed at strengthening its governance and supporting sustainable growth for the group. Representative Director and President and CEO Shuichi Watanabe will become Repr...
Activist Shareholder Pushes Governance and Capital Changes at Medipal Holdings
Sep 2, 2026
Medipal Holdings disclosed that a significant shareholder, The Northern Trust Company AVFC Re: Silchester International Investors International Value Equity Trust, has formally demanded an extraordinary general meeting under Japan’s Companie...
Medipal First-Quarter Profit Jumps as Dividend Plan Raised Despite Margin Pressure
Aug 5, 2026
Medipal Holdings reported first-quarter net sales of ¥989.5 billion, up 4.7% year on year, while operating profit slipped 4.7% and ordinary profit fell 1.7%. Profit attributable to owners of parent surged 42.3% to ¥13.6 billion, lifting ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.